Malignant NeoplasmsNCT00786656
Community Cancer Centers Pilot Patient Survey
An observational study of Malignant Neoplasms and Cancer, run by National Cancer Institute (NCI) at 1 site in United States.
Trial summary
Background: Studies suggest that cancer patients diagnosed and treated in a facility with multi-specialty care and clinical research may live longer and have a better quality of life than patients treated elsewhere. Read more about this study
- Who is it for?
- Ages 21 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Malignant Neoplasms, Cancer
- How many people
- 3,955 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Nov 2008to 11 May 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Living patients who are listed on an NCCCP site s cancer registry
- Cancer patients age 21 years and older at the time of sampling
- Cancer patients who had 1 or more cancer treatment outpatient visits at their cancer center since July 1, 2007 for the first survey round and since July 1, 2009 for the second round of the survey.
Who cannot join
- Persons under the age of 21 at the time of sampling.
- Persons not in the cancer registry
- Cancer patients without at least 1 or more cancer treatment outpatient visits since July 1, 2007 for the first survey round and since July 1, 2009 for the second round of the survey.
- Cancer patients who are deceased at the time of sampling
Trial locations and contacts
1 site in 1 country.
United States1 site
Research Triangle Institute International
Research Triangle Park, North Carolina, 27709
About this study
Official title: NCI Community Cancer Center Pilot Program Patient Survey
Background:
- Studies suggest that cancer patients diagnosed and treated in a facility with multi-specialty care and clinical research may live longer and have a better quality of life than patients treated elsewhere.
- The NCI Community Cancer Centers Pilot Program (NCCCP) is a 3-year program to test the concept of a national network of community cancer centers to expand cancer research and deliver the most advanced cancer care to Americans in their own communities.
- The pilot program includes a survey of cancer patients receiving care at the pilot sites.
Read more
Objectives:
- To gain an understanding of the experiences of adult patients who receive services at the NCCCP pilot sites and assess if and how their experience changes over the study period. Data about the following are collected:
- Patients information needs and awareness of the NCCCP program
- Clinical trials experience
- Access to health care
- Perspectives on patient-provider communication
- Experiences with patient navigation, self-management, medical decision-making and survivorship
- Satisfaction with care and quality of life
Eligibility:
- Patients 21 years or older at the time of diagnosis
- Treatment at the cancer center for at least 3 months since July 1, 2007
Design:
- Participants complete a 25-minute questionnaire covering the care they received at their cancer center, their experience with making medical appointments and how long they waited to see the doctor. The survey includes information on the following:
- Services at the cancer center
- Getting needed care
- Assistance for patients and their families
- Communication with the cancer care team
- Clinical trials
- Care after finishing treatment
- Evaluation of care
- Health and medical history
- Background information (demographics)
Read the detailed description
BACKGROUND:
The NCI Community Cancer Centers Pilot Program (NCCCP), http://ncccp.cancer.gov, is a three-year pilot program to test the concept of a national network of community cancer centers to expand cancer research and deliver the latest, most advanced cancer care to a greater number of Americans in the communities in which they live.The pilot program is designed to encourage the collaboration of private-practice medical, surgical, and radiation oncologists, with close links to NCI research and to the network of 63 NCI-designated cancer Centers principally based at large research universities. NCI contracted with RTI International (ww.rti.org) to conduct a comprehensive evaluation of the NCCCP pilot program using multiple methodologies, including a survey of cancer patients receiving care at the pilot sites.
OBJECTIVES:
The goal of the patient survey is to gain an understanding of the clinical experiences of adult patients who receive services at the NCCCP pilot sites and to assess if and how their experience change over the pilot period. Specifically, the survey instrument seeks to collect data about patients information needs and awareness of the NCCCP program; clinical trials experience; access to health care; perspectives on patient-provider communication; and experiences with patient navigation, self-management, medical decision making, and survivorship; as well as their satisfaction with care and quality of life.
ELIGIBILITY:
Each of the ten participating Centers will create a de-identified electronic file of all patients who meet the inclusion criteria:
- living patients who are listed on a NCCCP site s cancer registry;
- cancer patients age 21 years and older at the time of sampling; and
- cancer patients who had 1or more cancer treatment outpatient visits at their Cancer Center since July 1, 2007 for the 1st round of data collection, and since July 1, 2009 for the second data collection. Center will create this file using their cancer registry and assign each individual a unique identification (ID) number.
DESIGN:
Each file containing the universe of eligible patients will be sent to RTI, from which 475 patients from each Center s list will be randomly selected. RTI will send a list back to each Center indicating which 475 patient IDs were selected for inclusion in the survey. The Center staff will match selected patient back to their master list using the Study ID number to identify patients included in the survey. RTI will deliver 475 pre-paid patient survey packets to each Center. The packets will include all required items except a Patient Notification Letter, which is a cover letter introducing the study and provides instructions on how to complete the survey. To protect patient privacy, Center staff will be responsible for generating the mailing labels and personalized Patient Notification Letter, and mailing the packets.
- Conditions
- Malignant Neoplasms, Cancer
- Keywords
- Navigation, Coordination, Cancer Care, Patient Experience, Cancer, Patient Survey
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of NCCCP Pilot Program
Secondary outcomes (1)
Gain an understanding of the patients' perspective on the NCCCP Pilot Program and to assess how well health care and informational needs are being met.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2008 (estimated)
- Study start3 Nov 2008
- Study completion11 May 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant NeoplasmsStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 3,955 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Irene P Prabhu Das, Ph.D., Principal investigator, National Cancer Institute (NCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00786656
- Sponsor's protocol ID
- 999909026
- Other IDs
- 09-C-N026
- Status last verified
- 11 May 2015
- First submitted
- 5 Nov 2008
- Last updated
- 17 Dec 2019
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NCI Community Cancer Center Pilot Program Patient Survey
- ClinicalTrials.gov ID
- NCT00786656
- Acronym / sponsor ID
- 999909026
- Conditions
- Malignant Neoplasms, Cancer
- Keywords
- Navigation, Coordination, Cancer Care, Patient Experience, Cancer, Patient Survey
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,955 participants (actual)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 3 Nov 2008
- Study completion
- 11 May 2015
- First posted
- 6 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
- Studies suggest that cancer patients diagnosed and treated in a facility with multi-specialty care and clinical research may live longer and have a better quality of life than patients treated elsewhere.
- The NCI Community Cancer Centers Pilot Program (NCCCP) is a 3-year program to test the concept of a national network of community cancer centers to expand cancer research and deliver the most advanced cancer care to Americans in their own communities.
- The pilot program includes a survey of cancer patients receiving care at the pilot sites.
Objectives:
- To gain an understanding of the experiences of adult patients who receive services at the NCCCP pilot sites and assess if and how their experience changes over the study period. Data about the following are collected:
- Patients information needs and awareness of the NCCCP program
- Clinical trials experience
- Access to health care
- Perspectives on patient-provider communication
- Experiences with patient navigation, self-management, medical decision-making and survivorship
- Satisfaction with care and quality of life
Eligibility:
- Patients 21 years or older at the time of diagnosis
- Treatment at the cancer center for at least 3 months since July 1, 2007
Design:
- Participants complete a 25-minute questionnaire covering the care they received at their cancer center, their experience with making medical appointments and how long they waited to see the doctor. The survey includes information on the following:
- Services at the cancer center
- Getting needed care
- Assistance for patients and their families
- Communication with the cancer care team
- Clinical trials
- Care after finishing treatment
- Evaluation of care
- Health and medical history
- Background information (demographics)
Detailed description
BACKGROUND:
The NCI Community Cancer Centers Pilot Program (NCCCP), http://ncccp.cancer.gov, is a three-year pilot program to test the concept of a national network of community cancer centers to expand cancer research and deliver the latest, most advanced cancer care to a greater number of Americans in the communities in which they live.The pilot program is designed to encourage the collaboration of private-practice medical, surgical, and radiation oncologists, with close links to NCI research and to the network of 63 NCI-designated cancer Centers principally based at large research universities. NCI contracted with RTI International (ww.rti.org) to conduct a comprehensive evaluation of the NCCCP pilot program using multiple methodologies, including a survey of cancer patients receiving care at the pilot sites.
OBJECTIVES:
The goal of the patient survey is to gain an understanding of the clinical experiences of adult patients who receive services at the NCCCP pilot sites and to assess if and how their experience change over the pilot period. Specifically, the survey instrument seeks to collect data about patients information needs and awareness of the NCCCP program; clinical trials experience; access to health care; perspectives on patient-provider communication; and experiences with patient navigation, self-management, medical decision making, and survivorship; as well as their satisfaction with care and quality of life.
ELIGIBILITY:
Each of the ten participating Centers will create a de-identified electronic file of all patients who meet the inclusion criteria:
- living patients who are listed on a NCCCP site s cancer registry;
- cancer patients age 21 years and older at the time of sampling; and
- cancer patients who had 1or more cancer treatment outpatient visits at their Cancer Center since July 1, 2007 for the 1st round of data collection, and since July 1, 2009 for the second data collection. Center will create this file using their cancer registry and assign each individual a unique identification (ID) number.
DESIGN:
Each file containing the universe of eligible patients will be sent to RTI, from which 475 patients from each Center s list will be randomly selected. RTI will send a list back to each Center indicating which 475 patient IDs were selected for inclusion in the survey. The Center staff will match selected patient back to their master list using the Study ID number to identify patients included in the survey. RTI will deliver 475 pre-paid patient survey packets to each Center. The packets will include all required items except a Patient Notification Letter, which is a cover letter introducing the study and provides instructions on how to complete the survey. To protect patient privacy, Center staff will be responsible for generating the mailing labels and personalized Patient Notification Letter, and mailing the packets.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 21 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Living patients who are listed on an NCCCP site s cancer registry
- Cancer patients age 21 years and older at the time of sampling
- Cancer patients who had 1 or more cancer treatment outpatient visits at their cancer center since July 1, 2007 for the first survey round and since July 1, 2009 for the second round of the survey.
Key exclusion criteria (4 listed)
- Persons under the age of 21 at the time of sampling.
- Persons not in the cancer registry
- Cancer patients without at least 1 or more cancer treatment outpatient visits since July 1, 2007 for the first survey round and since July 1, 2009 for the second round of the survey.
- Cancer patients who are deceased at the time of sampling
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of NCCCP Pilot Program
1 secondary outcome
Gain an understanding of the patients' perspective on the NCCCP Pilot Program and to assess how well health care and informational needs are being met.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2019.
Related trials for Malignant Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Irene P Prabhu Das, Ph.D. principal investigator
National Cancer Institute (NCI)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Neoplasms and Cancer, run by National Cancer Institute (NCI) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of NCCCP Pilot Program. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2019.